An interventional study of Heart Age and Heart Age-HOPE-CVD App in Cardiovascular Diseases (CVD), sponsored by Nanyang Technological University. Status unknown at 1 site in Singapore. Open to participants aged 30 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Nanyang Technological University · Not applicable, Interventional, and Prevention
This pragmatic four-arm (1:1:1:1) parallel cluster randomised controlled trial (cRCT) aims to evaluate the effectiveness of reducing the risk of cardiovascular disease (CVD) through three combinations of interventions for individuals at risk of CVD in the primary care setting in Singapore. These interventions are a) communicating an individual's phenotypic risk of CVD, b) a digital psychoeducation application (Heart Age-HOPE-CVD app) that supports health-promoting behavioural change, and c) communicating an individual's genetic risk of CVD. Our study hypothesis is that the exposure of these three interventions will have additive effects on the primary and secondary objectives.
The primary objective of our study is to evaluate the impact of each intervention arm compared to usual care (Arm 1) on the risk for CVD, using change in low-density lipoprotein cholesterol (LDL) measurements as the outcome measure. The secondary objective is to evaluate the impact of each intervention arm compared to usual care (Arm 1) on the following: (a) individual CVD risk factors (i.e. blood pressure, total cholesterol, high-density lipoprotein, body mass index, smoking status, fasting blood glucose or glycated haemoglobin, diagnosis of diabetes, triglycerides level), (b) risk for CVD (i.e., estimated using the Framingham Risk Score), (c) health-related quality of life and well-being, and (d) practice of health-promoting behaviours.
The Heart Age-HOPE-CVD app is a 6-month interventional programme. Hence, the effects of the interventions will be evaluated after a 6-month period. Patients will be recruited by general practitioners (GPs) at primary care clinics around Singapore. After obtaining informed consent at baseline, patients' data will be collected at four time points: baseline, mid-intervention at week 6, post-intervention health screening at week 24 and post-intervention at week 26. All data collection will be conducted at the primary care clinic, except for mid-intervention data which will be collected via an online form.
5,025 studies on the registry are indexed under Cardiovascular Diseases; 930 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 100 across 2,801 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Nanyang Technological University is the lead sponsor of 50 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
* General practitioners' (GPs) usual care for patients. * GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website.
* General practitioners' (GPs) usual care for patients. * GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website. * GPs will also show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value.
Behavioral: Heart Age
* General practitioners' (GPs) usual care for patients. * GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website. * GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value. * GPs will also direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform.
Behavioral: Heart Age · Behavioral: Heart Age-HOPE-CVD App
* General practitioners' (GPs) usual care for patients. * GPs will direct patient participants to a publicly available webpage about managing CVD risk on the Health Promotion Board website. * GPs will show patient participants how to access Heart Age, a risk assessment tool available online and communicate with them their respective Heart Age value. * GPs will direct patient participants to download the Heart Age-HOPE- CVD mobile app, an evidence-based behaviour change digital platform. * Patient participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. They will be informed which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
Behavioral: Heart Age · Behavioral: Heart Age-HOPE-CVD App · Behavioral: Communication of Genetic Risk Score
Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
Change in low density lipoprotein
Low-density lipoprotein cholesterol will be measured and compared between the measurements at baseline and post-intervention health screening.
Time frame: Week 0 and Week 24
Change in 10-year predicted absolute risk of cardiovascular disease
Patients' baseline and post-intervention 10-year predicted absolute cardiovascular disease risk will be calculated and compared by a version of the Framingham Risk Score, which is used in the Heart Age algorithm. The variables (i.e., age, total cholesterol, high-density lipoprotein cholesterol, diabetes prevalence, smoking status, systolic blood pressure, and prescription of anti-hypertensive medications) needed for this algorithm will be measured or obtained at the baseline and post-intervention health screening visits. These variables will be aggregated into a percentage score ranging from 0-100%, where a higher percentage indicates a higher 10-year predicted absolute risk of CVD. A reduction in the percentage score is a better outcome.
Time frame: Week 0 and from Week 24
Change in systolic blood pressure
Systolic blood pressure will be measured and compared between the measurements at baseline and post-intervention health screening visits.
Time frame: Week 0 and from Week 24
Change in total cholesterol
Total cholesterol will be measured and compared between the measurements at baseline and post-intervention health screening visits.
Time frame: Week 0 and from Week 24
Change in high-density lipoprotein cholesterol
High-density lipoprotein cholesterol will be measured and compared between the measurements at baseline and post-intervention health screening visits.
Time frame: Week 0 and from Week 24
Change in body mass index
Body mass index (BMI) will be compared between the measurements at baseline and post-intervention health screening visits. BMI will be calculated by dividing weight in kilograms and the square of height in metres (kg/m2).
Time frame: Week 0 and from Week 24
Change in smoking habit
Smoking status will be compared between baseline and post-intervention screening visits. The GP will ask the patient participant if she/he is a smoker at the baseline and post-intervention screening visits, and the GP will collect a "Yes" or "No" response.
Time frame: Week 0 and from Week 24
Change in fasting blood glucose or glycated haemoglobin measurement
The fasting blood glucose or glycated haemoglobin will be measured and compared between the measurements at baseline and post-intervention health screening visits.
Time frame: Week 0 and from Week 24
Change in diagnosis of diabetes
The diagnosis of diabetes will be compared between baseline and post-intervention screening visits. The GP will ask the patient participant if she/he is a smoker at the baseline and post-intervention screening visits, and the GP will collect a "Yes" or "No" response.
Time frame: Week 0 and from Week 24
Change in triglycerides
The triglycerides will be measured and compared between the measurements at baseline and post-intervention health screening visits.
Time frame: Week 0 and from Week 24
Changes in health-promoting behaviours
Health-promoting behaviours will be measured using self-reported questionnaires at baseline, 6 weeks, and 6 months to observe changes over the course of the study. This will be measured using the Readiness for Change questionnaire using a scale of 1 to 40, where a higher score indicates a better outcome.
Time frame: Week 0, Week 6, and Week 24
Change in goal-directed behaviours for living well
Goal-directed behaviours for living well support a process-based approach to well-being which will be measured and compared between baseline and post-intervention follow-up visits using items in the "EvalUationof goal-diRectedbehaviOurstoPromotewell-beIngandheAlth" scale (Euroia-14). There are 18 items on the Euroia-14 that are separated into four sub-scales (i.e. Self-Affirmation, Social Affiliation, Social Roles and Responsibilities, and Eudemonic). All 18 items are scored between 1 and 4, with a higher score indicating a better outcome.
Time frame: Week 0 and from Week 24
Change in health-related quality of life
Health-related quality of life will be assessed and compared between baseline and post-intervention follow-up visits using the items from the validated instrument "Short Form 36 version 2" (SF-36v2).
Time frame: Week 0 and from Week 24
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanyang Technological University